Vaccine Immunogenicity and Efficacy

Immunogenicity is the ability of a vaccine to provoke a measurable immune response; efficacy is the protection it provides against disease under the controlled conditions of a clinical trial. A vaccine may be highly immunogenic yet of uncertain efficacy until protection is demonstrated against clinical outcomes, which is why the two concepts are evaluated together but kept distinct.

Definition

Vaccine immunogenicity is the capacity of a vaccine to elicit a measurable immune response, and vaccine efficacy is the proportional reduction in disease incidence among vaccinated relative to unvaccinated participants observed in a controlled trial.

Scope

The topic covers how immunogenicity is measured (antibody titres, neutralization, cellular responses), how vaccine efficacy is defined and estimated in randomized trials, and the relationship between the two. It is reference material on how vaccines are evaluated, not clinical advice.

Core questions

• What immune responses does a vaccine elicit, and how are they quantified?
• How is vaccine efficacy defined and estimated in a randomized trial?
• Why can a vaccine be immunogenic without a guaranteed level of clinical protection?

Key concepts

• Immunogenicity endpoints (titre, neutralization, T-cell response)
• Seroconversion and seroprotection
• Vaccine efficacy (relative risk reduction)
• Randomized controlled efficacy trial
• Geometric mean titre
• Primary and booster dosing schedule
• Reactogenicity versus immunogenicity

Mechanisms

Immunogenicity reflects the magnitude, quality, and durability of the immune response a vaccine induces, including antibody production, neutralizing activity, and antigen-specific T-cell responses, supported by immunological memory. Efficacy is measured by comparing disease incidence between randomized vaccinated and placebo groups; the COVID-19 mRNA vaccine trials, for example, reported high efficacy against symptomatic disease, illustrating how trial design translates an immune response into a quantified protective effect.

Clinical relevance

Immunogenicity and efficacy data are the basis on which vaccines are licensed and recommended, and understanding them supports appraisal of vaccine evidence. The topic describes how vaccine performance is established and is not a basis for individual clinical decisions.

Epidemiology

Efficacy is established in randomized trials in defined populations and conditions; how that protection generalizes to routine use is addressed separately through effectiveness studies. Immunogenicity data are also used to bridge between populations, age groups, and vaccine formulations when full efficacy trials are not feasible.

Evidence & guidelines

General principles are summarized in vaccinology reviews, and the pivotal COVID-19 vaccine randomized trials provide widely cited illustrations of efficacy estimation. These are reference syntheses and trial reports, not prescriptive guidelines.

History

Quantitative immunogenicity testing grew out of early serological assays for antibody responses, and the randomized controlled trial became the standard for establishing vaccine efficacy across the twentieth century. The COVID-19 pandemic produced an unusually rapid succession of large efficacy trials that brought the immunogenicity-efficacy distinction to wide attention.

Debates

How well does immunogenicity predict efficacy?

A strong immune response does not automatically guarantee a defined level of protection, so immunogenicity data alone are generally insufficient to establish efficacy unless a validated correlate of protection links the two.

Key figures

• Andrew J. Pollard
• Stanley A. Plotkin
• Fernando P. Polack
• Lindsey R. Baden

Seminal works

• pollard-bijker-2021
• polack-2020
• baden-2021

Frequently asked questions

Is an immunogenic vaccine always an effective one?

Not necessarily. Immunogenicity shows that the vaccine elicits an immune response, but efficacy requires demonstrating that this response actually reduces disease, which is established in clinical trials and, ideally, linked through a validated correlate of protection.

How is vaccine efficacy expressed?

It is usually expressed as the percentage reduction in disease incidence among vaccinated participants compared with unvaccinated participants in a randomized trial, for example an efficacy of 90 percent meaning a 90 percent lower rate of the outcome in the vaccinated group.